Pricing Log in Create free account
Friday 6 November 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.3%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

167.46 7.02 −4.02%
Market cap
$207.8B
P/E
0.0×
Fwd P/E
−41.3×
Dividend yield
1.94%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Gilead Sciences, Inc. (GILD) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Gilead Sciences, Inc. (GILD) trades at a EV/EBITDA of 505×. Over the past ten years it has ranged from 5.4× (December 2016) to 812× (September 2026); the current reading is higher than 98% of that period. That is above the Drug Manufacturers General industry median of 14.8× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 13.3× (55.34%)
FY2024 29.8× 149.58%
FY2023 11.9× (11.50%)
FY2022 13.5× 43.63%
FY2021 9.4× (47.06%)
FY2020 17.7× 20.47%
FY2019 14.7× 78.38%
FY2018 8.3× 20.61%
FY2017 6.8× 12.05%
FY2016 6.1× (8.82%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 454× (33.91%)
Jun 2026 687× 4,708.00%
Mar 2026 14.3× 7.51%
Dec 2025 13.3× 13.33%
43 more quarters

Against its own ten years

Low 5.4× High 812×
Ten-year median 10.6×
Current reading's percentile 98

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.3×
PFE Pfizer Inc. compare 10.9×
BMY Bristol Myers Squibb Company compare 11.3×
SNY Sanofi compare 11.4×
AZN AstraZeneca PLC compare 14.8×
NVS Novartis AG compare 15.6×
AMGN Amgen Inc. compare 17.6×
MRK Merck & Co., Inc. compare 29.7×
GILD Gilead Sciences, Inc. 505×
Drug Manufacturers General industry median 14.8×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on GILD